Skip to content

Modified Valsalva Effectivness in Re-entrant Tachycardias (REVERT) study

Randomised Evaluation of Modified Valsalva Effectivness in Re-entrant Tachycardias (REVERT) study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN67937027
Enrollment
372
Registered
2013-02-14
Start date
2013-01-13
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Re-entrant Tachycardia Circulatory System Re-entry ventricular arrhythmia

Interventions

Control - Standard VM, Normal Valsalva strain at 40mmHg for 15 seconds in a semi-recumbent position, remaining in this position for 60 seconds after strain before reviewing ECG for cardioversion. Int

Sponsors

Royal Devon and Exeter Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18 years and over 2. Stable male or female adult patients presenting to the Emergency Department with SVT (regular, narrow complex tachycardia with QRS duration <0.12ms on ECG) 3. Written informed consent to participate

Exclusion criteria

Exclusion criteria: 1. Unstable patient (BP 220mmHg or diastolic >120mmHg) 5. Any contraindication to or inability to performing a VM 6. Contraindication or inability to lay flat or lift legs 7. 3rd trimester pregnancy 8. Patients without capacity to provide written informed consent 9. Previous inclusion in the study

Design outcomes

Primary

MeasureTime frame
The presence of sinus rhythm post Valsalva as determined by a 12 lead ECG.; Timepoint(s): 1 minute post-Valsalva

Secondary

MeasureTime frame
1. Adverse events; Timepoint(s): From time of consent until discharge from emergency department (ED) 2. The need for hospital admission Timepoint(s): Post-Valsalva until discharge from ED. 3. Time spent in ED; Timepoint(s): From time of admission until discharge from ED. 4. Use of other emergency treatments for SVT in ED; Timepoint(s): Post-Valsalva until discharge from ED

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 15, 2026